29 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2031
Next term end
11
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2036 · High confidence
Also notable
Ends Jan 2038 · Low confidence
Also notable
Ends Sep 2037 · Medium confidence
Beta-D-2'-Deoxy-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
US 9,828,410
The most cited patent in this portfolio, cited by 43 later US patents, top 10% of utility patents granted in 2017 in our data. Protection runs to 2036.
Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus
US 10,906,928
Cited by 16 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment
US 10,946,033
Cited by 18 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 4 to 25, 2027 · next Jan 4
- 1 fee due Feb 28, 2027The maintenance fee for Highly Active Compounds Against COVID-19 (US 11,738,038) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Highly Active Compounds Against COVID-19 (US 11,813,278) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus (US 10,519,186) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for 2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment (US 11,975,016) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 17, 2026
What they patent
The 5 largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Beta-D-2'-Deoxy-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | 9 in force | to Mar 2036 |
| Nucleotide Hemi-Sulfate Salt for the Treatment of Hepatitis C Virus | 5 in force | to Apr 2038 |
| Highly Active Compounds Against COVID-19 (2021) | 3 in force | to Mar 2041 |
| Highly Active Compounds Against COVID-19 (2020) | 3 in force | to Sep 2040 |
| 2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment | 2 in force | to Sep 2037 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,458,656 | Advantageous Anti-Hcv Combination Therapy In force · Low confidence | In force | Low confidence | |
| US 12,778,975 | Advantageous Anti-Hcv Combination Therapy In force · Low confidence | In force | Low confidence | |
| US 9,828,410 | Beta-D-2'-Deoxy-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT In force · High confidence | In force | High confidence | |
| US 10,000,523 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | In force | High confidence | |
| US 10,005,811 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | In force | High confidence | |
| US 10,239,911 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | In force | High confidence | |
| US 10,815,266 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | In force | High confidence | |
| US 10,870,672 | Beta-D-2'-Deoxy-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT In force · High confidence | In force | High confidence | |
| US 10,870,673 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | In force | High confidence | |
| US 10,875,885 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | In force | High confidence |
Also on record, not counted in the 29: 6 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.